Oral-tolerization prevents immune responses and improves transgene persistence following gene transfer mediated by adeno-associated viral vector

Molecular Therapy

Volumn 24, Issue 1, 2016, Pages 87-95

  Hardet, Romain ^a,b   Chevalier, Benjamin ^a,b   Dupaty, Léa ^a,b   Naïmi, Yassine ^a,b   Riou, Gaëtan ^a,b   Drouot, Laurent ^a,b   Jean, Laetitia ^a,b   Salvetti, Anna ^c,d,e,f   Boyer, Olivier ^a,b,g   Adriouch, Sahil ^a,b  

^a INSERM   (France)

^b UNIVERSITY OF ROUEN   (France)

^c CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^d UNIVERSITÉ DE LYON   (France)

^e UNIVERSITÉ LYON 1   (France)

^f UNIVERSITÉ DE LYON   (France)

^g ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BCL 2; OVALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; FEMALE; GENE DELETION; GENE EXPRESSION; GENE TRANSFER; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MOUSE; MOUSE MODEL; NONHUMAN; PROPHYLAXIS; TRANSGENE; UPREGULATION; ADMINISTRATION AND DOSAGE; ANIMAL; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOLOGY; DEPENDOPARVOVIRUS; DRUG EFFECTS; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; IMMUNE TOLERANCE; INJECTIONS, INTRAMUSCULAR; MICE; OVALBUMIN; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84957842727     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.146     Document Type: Article

References (58)

1. Wang, L and Herzog, RW (2005). AAV-mediated gene transfer for treatment of hemophilia. Curr Gene Ther 5: 349-360
2. Mingozzi, F and High, KA (2011). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12: 341-355
3. Zincarelli, C, Soltys, S, Rengo, G and Rabinowitz, JE (2008). Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16: 1073-1080
4. Petrs-Silva, H and Linden, R (2013). Advances in recombinant adeno-associated viral vectors for gene delivery. Curr Gene Ther 13: 335-345
5. Mays, LE and Wilson, JM (2011). The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol Ther 19: 16-27
6. Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr, Mingozzi, F, Bennicelli, J., et al. (2008). Safety and efficacy of gene transfer for Lebers congenital amaurosis. N Engl J Med 358: 2240-2248
7. Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ., et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347
8. Gaudet, D, M?hot, J, D?y, S, Brisson, D, Essiembre, C, Tremblay, G., et al. (2013). Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther 20: 361-369
9. Mingozzi, F, Maus, MV, Hui, DJ, Sabatino, DE, Murphy, SL, Rasko, JE., et al. (2007). CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 13: 419-422
10. Nayak, S and Herzog, RW (2010). Progress and prospects: immune responses to viral vectors. Gene Ther 17: 295-304
11. Mingozzi, F and High, KA (2011). Immune responses to AAV in clinical trials. Curr Gene Ther 11: 321-330
12. Manning, WC, Zhou, S, Bland, MP, Escobedo, JA and Dwarki, V (1998). Transient immunosuppression allows transgene expression following readministration of adenoassociated viral vectors. Hum Gene Ther 9: 477-485
13. Fields, PA, Kowalczyk, DW, Arruda, VR, Armstrong, E, McCleland, ML, Hagstrom, JN., et al. (2000). Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther 1: 225-235
14. Yuasa, K, Yoshimura, M, Urasawa, N, Ohshima, S, Howell, JM, Nakamura, A., et al. (2007). Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Gene Ther 14: 1249-1260
15. Gao, G, Wang, Q, Calcedo, R, Mays, L, Bell, P, Wang, L., et al. (2009). Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. Hum Gene Ther 20: 930-942
16. Wang, L, Dobrzynski, E, Schlachterman, A, Cao, O and Herzog, RW (2005). Systemic protein delivery by muscle-gene transfer is limited by a local immune response. Blood 105: 4226-4234
17. Wang, Z, Tapscott, SJ, Chamberlain, JS and Storb, R (2011). Immunity and AAVMediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials. Front Microbiol 2: 201
18. Ferreira, V, Twisk, J, Kwikkers, K, Aronica, E, Brisson, D, Methot, J., et al. (2014). Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum Gene Ther 25: 180-188
19. Wang, L, Cao, O, Swalm, B, Dobrzynski, E, Mingozzi, F and Herzog, RW (2005). Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther 12: 1453-1464
20. Manno, CS, Chew, AJ, Hutchison, S, Larson, PJ, Herzog, RW, Arruda, VR., et al. (2003). AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101: 2963-2972
21. Ferreira, V, Petry, H and Salmon, F (2014). Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside. Front Immunol 5: 82
22. Mingozzi, F and High, KA (2013). Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122: 23-36
23. Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC., et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365
24. Nathwani, AC, Reiss, UM, Tuddenham, EG, Rosales, C, Chowdary, P, McIntosh, J., et al. (2014). Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 371: 1994-2004
25. Coombes, JL, Siddiqui, KR, Arancibia-C?camo, CV, Hall, J, Sun, CM, Belkaid, Y., et al. (2007). A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 204: 1757-1764
26. Schulz, O, Jaensson, E, Persson, EK, Liu, X, Worbs, T, Agace, WW., et al. (2009). Intestinal CD103+, but not CX3CR1+, antigen sampling cells migrate in lymph and serve classical dendritic cell functions. J Exp Med 206: 3101-3114
27. Weiner, HL, da Cunha, AP, Quintana, F and Wu, H (2011). Oral tolerance. Immunol Rev 241: 241-259
28. Groux, H, OGarra, A, Bigler, M, Rouleau, M, Antonenko, S, De Vries, JE., et al. (1997). A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389: 737-742
29. Bilsborough, J, George, TC, Norment, A and Viney, JL (2003). Mucosal CD8alpha+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology 108: 481-492
30. Goubier, A, Dubois, B, Gheit, H, Joubert, G, Villard-Truc, F, Asselin-Paturel, C., et al. (2008). Plasmacytoid dendritic cells mediate oral tolerance. Immunity 29: 464-475
31. Chen, Y, Inobe, J, Marks, R, Gonnella, P, Kuchroo, VK and Weiner, HL (1995). Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 376: 177-180
32. Friedman, A and Weiner, HL (1994). Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci USA 91: 6688-6692
33. Zhang, X, Izikson, L, Liu, L and Weiner, HL (2001). Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. J Immunol 167: 4245-4253
34. Wherrett, DK, Bundy, B, Becker, DJ, DiMeglio, LA, Gitelman, SE, Goland, R et al.; Type 1 Diabetes TrialNet GAD Study Group. (2011). Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 378: 319-327
35. Dello Iacono, I, Tripodi, S, Calvani, M, Panetta, V, Verga, MC and Miceli Sopo, S (2013). Specific oral tolerance induction with raw hens egg in children with very severe egg allergy: a randomized controlled trial. Pediatr Allergy Immunol 24: 66-74
36. Chung, Y, Chang, SY and Kang, CY (1999). Kinetic analysis of oral tolerance: memory lymphocytes are refractory to oral tolerance. J Immunol 163: 3692-3698
37. Adriouch, S, Franck, E, Drouot, L, Bonneau, C, Jolinon, N, Salvetti, A., et al. (2011). Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer. Front Microbiol 2: 199
38. Franck, E, Bonneau, C, Jean, L, Henry, JP, Lacoume, Y, Salvetti, A., et al. (2012). Immunological tolerance to muscle autoantigens involves peripheral deletion of autoreactive CD8+ T cells. PLoS One 7: e36444
39. Dobrzynski, E, Mingozzi, F, Liu, YL, Bendo, E, Cao, O, Wang, L., et al. (2004). Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. Blood 104: 969-977
40. Hubert, S, Rissiek, B, Klages, K, Huehn, J, Sparwasser, T, Haag, F., et al. (2010). Extracellular NAD+ shapes the Foxp3+ regulatory T cell compartment through the ART2-P2X7 pathway. J Exp Med 207: 2561-2568
41. Resta, R, Yamashita, Y and Thompson, LF (1998). Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev 161: 95-109
42. Parish, IA, Rao, S, Smyth, GK, Juelich, T, Denyer, GS, Davey, GM., et al. (2009). The molecular signature of CD8+ T cells undergoing deletional tolerance. Blood 113: 4575-4585
43. Manning, WC, Paliard, X, Zhou, S, Pat Bland, M, Lee, AY, Hong, K., et al. (1997). Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J Virol 71: 7960-7962
44. Gagliani, N, Magnani, CF, Huber, S, Gianolini, ME, Pala, M, Licona-Limon, P., et al. (2013). Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 19: 739-746
45. Tsuji, NM, Mizumachi, K and Kurisaki, J (2001). Interleukin-10-secreting Peyers patch cells are responsible for active suppression in low-dose oral tolerance. Immunology 103: 458-464
46. Chen, Y, Inobe, J, Kuchroo, VK, Baron, JL, Janeway, CA Jr and Weiner, HL (1996). Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci USA 93: 388-391
47. Castro-Junior, AB, Horta, BC, Gomes-Santos, AC, Cunha, AP, Silva Steinberg, R, Nascimento, DS., et al. (2012). Oral tolerance correlates with high levels of lymphocyte activity. Cell Immunol 280: 171-181
48. Sun, J, Dirden-Kramer, B, Ito, K, Ernst, PB and Van Houten, N (1999). Antigen-specific T cell activation and proliferation during oral tolerance induction. J Immunol 162: 5868-5875
49. Robert, S, Gysemans, C, Takiishi, T, Korf, H, Spagnuolo, I, Sebastiani, G., et al. (2014). Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice. Diabetes 63: 2876-2887
50. Takiishi, T, Korf, H, Van Belle, TL, Robert, S, Grieco, FA, Caluwaerts, S., et al. (2012). Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest 122: 1717-1725
51. Rottiers, P, De Smedt, T and Steidler, L (2009). Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis. Int Rev Immunol 28: 465-486
52. Wang, X, Sherman, A, Liao, G, Leong, KW, Daniell, H, Terhorst, C., et al. (2013). Mechanism of oral tolerance induction to therapeutic proteins. Adv Drug Deliv Rev 65: 759-773
53. Kwon, KC, Verma, D, Singh, ND, Herzog, R and Daniell, H (2013). Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. Adv Drug Deliv Rev 65: 782-799
54. Verma, D, Moghimi, B, LoDuca, PA, Singh, HD, Hoffman, BE, Herzog, RW., et al. (2010). Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proc Natl Acad Sci USA 107: 7101-7106
55. Sherman, A, Su, J, Lin, S, Wang, X, Herzog, RW and Daniell, H (2014). Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cells. Blood 124: 1659-1668
56. Wang, X, Su, J, Sherman, A, Rogers, GL, Liao, G, Hoffman, BE., et al. (2015). Plantbased oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells. Blood 125: 2418-2427
57. Nayak, S, Sarkar, D, Perrin, GQ, Moghimi, B, Hoffman, BE, Zhou, S., et al. (2011). Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B. Front Microbiol 2: 244
58. Lauvau, G, Vijh, S, Kong, P, Horng, T, Kerksiek, K, Serbina, N., et al. (2001). Priming of memory but not effector CD8 T cells by a killed bacterial vaccine. Science 294: 1735-1739